These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36475205)

  • 1. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
    Chin E; Jaqua E; Safaeipour M; Ladue T
    Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
    Saeedi M; Mehranfar F
    Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.
    Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aducanumab: evidence from clinical trial data and controversies.
    Tampi RR; Forester BP; Agronin M
    Drugs Context; 2021; 10():. PubMed ID: 34650610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
    Esang M; Gupta M
    Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab in Alzheimer's disease: A critical update.
    Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K
    Curr Med Chem; 2023 Jul; ():. PubMed ID: 37497712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease and its treatment-yesterday, today, and tomorrow.
    Kim AY; Al Jerdi S; MacDonald R; Triggle CR
    Front Pharmacol; 2024; 15():1399121. PubMed ID: 38868666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.
    Shukla D; Suryavanshi A; Bharti SK; Asati V; Mahapatra DK
    Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38566385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Honyashiki M; Inoue T
    Ageing Res Rev; 2022 Nov; 81():101709. PubMed ID: 35961514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
    Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.